Ontario

General contact information for trials in Ontario:

Ottawa:

Toronto:

Hamilton:

Current trials:

VOYAGER Trial

Recruiting locations in Ontario:

ID Number: NCT03465722

Links:

Description: This study looks at the drug Avapritnib (BLU-285) for patients with advanced or metastatic a Gastrointestinal Stromal Tumor (GIST) compared to Regorafenib. Patients will take one of the two study drugs over 2 months and the researchers will compare their survival and disease status over time to decide which medication is more effective.

  • Group A will receive Avapritnib.
  • Group B will receive a Regorafenib.

Intervention: Both of the drugs being compared in this study are meant to stop cancer cells from spreading. Regorafenib is a kinase inhibitor. This means that it stops cancer cells from producing certain proteins they need to survive and divide. It is widely used to treat various types of cancer. Avapritnib looks like a promising new treatment which can stop cancer cells from dividing. This trial will help to figure out if it is helpful in treating a specific type of gastric cancer.

Can I consider participating?

  • Yes: adult patients with an unresectable GIST who have already been treated with a medication called imatinib, as well as 1-2 other medications which are tyrosine kinase inhibitors (TKIs)
  • No: patients who have been treated with Avapritnib or Regorafenib in the past; patients who have tried 3 or more TKI medications in the past

Keynote-585 Trial

Recruiting location in Ontario:

  • Toronto – Sunnybrook Health Sciences Centre (OCC Clinical Research Program: 416-480-5000)

ID Number: NCT03221426

Links:

Description: This study will be looking at the effects of the drug pembrolizumab as part of pre-surgical treatment. The drug will be given before and after gastric cancer surgery with different chemotherapy routines. This study will be comparing two things. First, pembrolizumab with chemotherapy will be compared to a placebo with chemotherapy. This is done to determine if it is helpful in general. Next, pembrolizumab given with systemic chemotherapy will be compared to pembrolizumab given with FLOT chemotherapy. FLOT is a commonly prescribed chemotherapy routine for gastric cancer patients. There will be four groups in this experiment:

  • Group A – pembrolizumab and systemic chemotherapy
  • Group B – placebo and systemic chemotherapy
  • Group C – pembrolizumab and FLOT chemotherapy
  • Group D – placebo and FLOT chemotherapy

The researchers think that this drug can improve outcomes for patients, by increasing overall survival and event-free survival. This means patients will live longer without a recurrence of cancer.

Intervention:

  • Pembrolizumab: Sometimes, cancer cells stop our immune system from recognizing the growth of a tumor.  This way, the cancer is effectively able to “hide” from our body’s defense mechanisms. Pembrolizumab reverses this effect of the cancer cells so they can be detected and fought off by our body.
  • Systemic Chemotherapy: cisplatin and capecitabine/5-fluorouracil
  • FLOT: docetaxel, oxaliplatin, 5-fluorouracil and leucovorin

Can I consider participating?

  • Yes: patients with a T3 gastric tumor and some cancerous lymph nodes, but no metastases. Have never been treated before and are planning on having surgery.
  • No: patients who are not eligible for surgery (e.g.: metastatic disease), have ever had pneumonitis, have a current infection, have ever had treatment with other immune or cancer therapies (chemo/radiation)

OPDIVO Trial

Recruiting locations in Ontario:

  • London – London Health Sciences Centre (Mark Vincent, MD: 519-685-8640)
  • Toronto – Princess Margaret Cancer Centre (Raymond Jang, Site 0110: 416-946-6508)
  • Ottawa – The Ottawa Hospital (Derek Jonker, MD: 613-737-7700 Ext. 70169)

ID Number: NCT02743494

Links:

Description: This study looks at the drug nivolumab for patients with advanced gastric cancer who have had surgery. The experiment will compare the survival of two patient groups after surgery:

  • Group A will receive Nivolumab.
  • Group B will receive a placebo instead.  

Intervention: Sometimes, cancer cells stop our immune system from recognizing the growth of a tumor.  This way, the cancer is effectively able to “hide” from our body’s immune defense mechanisms. Nivolumab is a drug which helps your immune system (T cells) find and attack cancerous cells. This means that it is a type of immunotherapy drug.

Can I consider participating?

  • Yes: patients who already had chemoradiotherapy and surgery for stage 2 or 3 esophageal or gastroesophageal cancer, however the disease is still present
  • No: patients who have stage 4 cancer, or did not have chemoradiotherapy before surgery

CheckMate649 Trial

Recruiting locations in Ontario:

  • Toronto – Princess Margaret Cancer Centre (Elena Elimova, Site 0067: 416-946-4501 Ext. 6508)
  • London – London Health Sciences Centre (Mark Vincent: (519) 685-8634)

ID Number: NCT02872116

Link:

Description: This trial is looking to better understand the immunotherapy drug Nivolumab. They want to know if Nivolumab is helpful, and which chemotherapy routine is best to pair it with. To figure this out, there will be five groups in this trial:

  • Group A – Nivolumab and Ipilimumab
  • Group B – Nivolumab and XELOX (Oxaliplatin and Capecitabine)
  • Group C – Nivolumab and FOLFOX (Oxaliplatin, Leucovorin and Fluorouracil)
  • Group D – XELOX only (Oxaliplatin and Capecitabine)
  • Group E – FOLFOX only (Oxaliplatin, Leucovorin and Fluorouracil)

Intervention: Nivolumab is a drug that helps your immune system (T cells) attack cancerous cells. It is a type of immunotherapy drug. Ipilimumab is also a immunotherapy drug. XELOX and FOLFOX are both chemotherapy routines which are commonly prescribed for gastric cancer patients.

Can I consider participating?

  • Yes: patients who have advanced gastric cancer, have not received treatment within the last 6 months, able to provide a tumor biopsy sample
  • No: patients who have cancer of the brain or spinal cord, autoimmune disease, or a current infection

MAGE-A4 Trial

Evaluation of the safety and efficacy of MAGE-A4 T-cell therapy in treating HLA-A2 positive tumors (Phase I trial)

Recruiting location in Ontario:

  • Toronto – Princess Margaret Cancer Centre (Dr. Marcus Butler: 416-946-4501 ext 5485)

ID Number: NCT03132922

Link:

Description: This is a Phase I trial. It is not limited to gastric cancer; many types of cancer patients whose tumor expresses the MAGE-A4 protein may participate. Because this is a Phase I trial, all participants will receive the treatment.

Intervention: This experimental treatment will give patients a genetically modified T-cell protein that helps attack cancer cells. They will be measuring the number of adverse events as well as how useful + long-lasting this therapy is. The researchers estimate that the trial will last over 3.5 years.

Can I consider participating?

  • Yes: patients with gastric cancer, whose cells express a specific protein (HLA-A2*) and whose tumor cells express the the MAGE-A4 protein. Their life expectancy needs to be at least 6 months.
  • No: patients whose cells do not express the correct surface protein, patients who have a current infection
  • *Note: HLA-type is determined by a blood test. Please consult your doctor for more information about this test.

JAVELIN-Medley Trial

Recruiting location in Ontario:

  • Toronto – Princess Margaret Cancer Centre (Dr. Albiruni Razak: 416-586-5371)

ID Number: NCT02554812

Link:

Description: This is a Phase II trial. It is looking at the effects of the drug Avelumab combined with other cancer therapies for treating advanced gastric tumors. There are many treatment groups in this trial, because the researchers are interested in testing various dosages of each drug, as well as different combinations. The drug combinations they will be testing are:

  • A: Avelumab and Utomilumab
  • B: Avelumab and PF-04518600
  • C: Avelumab and PD-0360324
  • D: Avelumab, Utomilumab and PF-04518600

Intervention: All of the medications involved in this trial are immunotherapeutic. They help our immune system’s T cells recognize and attack tumor cells. This trial is trying to understand the effects of the drugs in combination with each other, as well as determine the appropriate dose for each medication.

Can I consider participating?

  • Yes: patients with an advanced gastric tumor who have a life expectancy of at least 3 months. The tumor has not been treated with radiation or systemic chemotherapy within 1 year.
  • No: patients who are currently having immunotherapy, recently had surgery (within 4 weeks), current infection

PROGRESS Trial

Recruiting location in Ontario:

  • Hamilton – Hamilton Health Sciences (Dr. Pablo Serrano, via Marlie Valencia: 905-521-2100, Ext. 43921)

ID Number: NCT03445260

Link:

Description: This study is looking to understand the potential benefits of nutritional supplements for gastric cancer patients around the time of their surgery. Patients will either receive a nutritional supplement or a placebo. PROGRESS is a relatively small trial called a “feasibility” study. This means the results of this study will help to determine if a larger randomized trials should be created in the future to make more definite conclusions about the usefulness of nutritional supplements for gastric cancer patients.

Intervention: The nutritional supplements being tested in this study are:

  • Immunomodulation: a liquid diet which includes a lot of basic biomolecules which form the building blocks of our cells (arginine, RNA, omega-6 fatty acids) (name: INergy FLD)
  • Carbohydrate Loading: a sugar-based supplement given before surgery (name: PreCovery)
  • Protein Isolate: a protein supplement given before surgery (name: ISOlution)

Can I consider participating?

  • Yes: adult patients with gastric cancer who are having surgery
  • No: patients with digestive disorders, patients with diabetes, organ failure, or those who cannot tolerate food orally

TREMELIMUMAB/MEDI4736 Trial

Recruiting location in Ontario:

  • Toronto – contact AstraZeneca Cancer Study Locator Service (1-8777-400-4656, AstraZeneca@emergingmed.com) for site specific details and enrolment information

ID Number: NCT02340975

Link:

Description: This is a Phase II trial. The researchers are trying to understand what the best dose of the drug MEDI4736 is for patients with metastatic or recurrent gastric cancer. This drug will be tested in combination with an immunotherapy medication called tremelimumab. There are five groups in this study:

  • Group A: MEDI4736 and Tremelimumab (dose 1)
  • Group B: MEDI4736 only
  • Group C: Tremelimumab only
  • Group D: MEDI4736 and Tremelimumab (dose 2)
  • Group E: MEDI4736 and Tremelimumab (dose 3)

Groups D and E are “third line” patients. This means that the original (first/second line) treatment they were receiving before did not work, or stopped working. Group E is consists only of patients who express specific biomarkers (for example: a certain protein) on the surface of their cells.

Intervention: MEDI4736 and Tremelimumab are both immunotherapeutic drugs. They work to help our body’s T cells find and destroy cancer cells.

Can I consider participating?

  • Yes: patients who have metastatic or recurrent gastric or gastroesophageal cancer, those who have tried other chemotherapy and treatments in the past which have not worked, must be able to provide a tumor biopsy
  • No: patients currently having chemotherapy, hormonal therapy or radiotherapy, patients who have had immunotherapeutic treatment for their cancer in the past